Mechanisms of LRRK2-mediated neurodegeneration

Current Neurology and Neuroscience Reports

Volumn 12, Issue 3, 2012, Pages 251-260

  Tsika, Elpida ^a   Moore, Darren J ^a  

^a Brain Mind Institute   (Switzerland)

Author keywords

Animal models; Autophagy; LRRK2; Microtubules; Neurite outgrowth; Neurodegeneration; Neuronal cell death; Neuronal toxicity; PARK8; Parkinson's disease; Parkinsonism; Protein aggregation; Protein kinase

Indexed keywords

GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN SERINE THREONINE KINASE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE;

ACTIN FILAMENT; AUTOPHAGY; CELL INCLUSION; CELL MIGRATION; CELL STRUCTURE; CELLULAR DISTRIBUTION; ENZYME ACTIVITY; ENZYME LOCALIZATION; GENE; GENE EXPRESSION; GENE MUTATION; GENE STRUCTURE; GENETIC ASSOCIATION; HUMAN; LEUCINE RICH REPEAT KINASE 2 GENE; MICROTUBULE; MITOCHONDRION; MOLECULAR PATHOLOGY; NERVE CELL LESION; NERVE DEGENERATION; NEURITE; NONHUMAN; PARKINSON DISEASE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSGENIC MOUSE; VESICULAR TRAFFICKING;

AUTOPHAGY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MITOCHONDRIA; MODELS, MOLECULAR; MUTATION; NEURODEGENERATIVE DISEASES; PROTEIN-SERINE-THREONINE KINASES;

EID: 84861232484     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-012-0265-8     Document Type: Review

References (94)

1. Gasser T: Mendelian forms of Parkinson's disease. Biochim Biophys Acta 2009, 1792:587-596.
2. Lang AE, Lozano AM: Parkinson's Disease. First of Two Parts. N Engl J Med 1998, 339:1044-1053. (Pubitemid 28457867)
3. Lang AE, Lozano AM: Parkinson's disease. Second of Two Parts. N Engl J Med 1998, 339:1130-1143. (Pubitemid 28465762)
4. Paisán-Ruiz C, Jain S, Evans EW et al.: Cloning of the gene containing mutations that cause PARK8-linked Parkinson's Disease. Neuron 2004, 44:595-600. (Pubitemid 39531224)
5. Zimprich A, Biskup S, Leitner P et al.: Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607. (Pubitemid 39531225)
6. Simon-Sanchez J, Schulte C, Bras JM et al.: Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009, 41:1308-1312.
7. Satake W, Nakabayashi Y, Mizuta I et al.: Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009, 41:1303-1307.
8. Biskup S, West AB: Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta 2009, 1792:625-633.
9. Healy DG, Falchi M, O'Sullivan SS et al.: Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008, 7:583-590.
10. Giasson BI, Covy JP, Bonini NM et al.: Biochemical and pathological characterization of Lrrk2. Annals of Neurology 2006, 59:315-322. (Pubitemid 43202485)
11. Ross OA, Toft M, Whittle AJ et al.: Lrrk2 and Lewy body disease. Ann Neurol 2006, 59:388-393. (Pubitemid 43202496)
12. Wszolek ZK, Pfeiffer RF, Tsuboi Y et al.: Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004, 62:1619-1622. (Pubitemid 38608210)
13. Mata IF, Wedemeyer WJ, Farrer MJ et al.: LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 2006, 29:286-293.
14. Berger Z, Smith KA, LaVoie MJ: Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 2010, 49:5511-5523.
15. Greggio E, Zambrano I, Kaganovich A et al.: The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 2008, 283:16906-16914.
16. Deng J, Lewis PA, Greggio E et al.: Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A 2008, 105:1499-1504. (Pubitemid 351346543)
17. Sen S, Webber PJ, West AB: Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J Biol Chem 2009, 284:36346-36356.
18. Jorgensen ND, Peng Y, Ho CCY et al.: The WD40 domain is required for LRRK2 neurotoxicity. PLoS One 2009, 4:e8463.
19. Biskup S, Moore D, Rea A et al.: Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci 2007, 8:102.
20. Biskup S, Moore DJ, Celsi F et al.: Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 2006, 60:557-569. (Pubitemid 44871798)
21. Galter D, Westerlund M, Carmine A et al.: LRRK2 expression linked to dopamine-innervated areas. Ann Neurol 2006, 59:714-719.
22. Higashi S, Biskup S, West AB et al.: Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res 2007, 1155:208-219. (Pubitemid 46900930)
23. Higashi S, Moore DJ, Colebrooke RE et al.: Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J Neurochem 2007, 100:368-381. (Pubitemid 46010998)
24. Westerlund M, Belin AC, Anvret A et al.: Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease. Neuroscience 2008, 152:429-436.
25. Piccoli G, Condliffe SB, Bauer M et al.: LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci 2011, 31:2225-2237.
26. Tong Y, Giaime E, Yamaguchi H et al.: Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener 2012, 7:2.
27. Tong Y, Yamaguchi H, Giaime E et al.: Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 2010, 107:9879-9884.
28. Herzig MC, Kolly C, Persohn E et al.: LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 2011, 20:4209-4223.
29. Melrose H, Lincoln S, Tyndall G et al.: Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 2006, 139:791-794. (Pubitemid 44308089)
30. Alegre-Abarrategui J, Christian H, Lufino MMP et al.: LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 2009, 18:4022-4034.
31. Hatano T, Kubo S, Imai S et al.: Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 2007, 16:678-690. (Pubitemid 46585667)
32. Dodson MW, Zhang T, Jiang C et al.: Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet 2011, Dec 30, Epub.
33. Gloeckner CJ, Schumacher A, Boldt K, Ueffing M: The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem 2009, 109:959-968.
34. Hsu CH, Chan D, Greggio E et al.: MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J Neurochem 2010, 112:1593-1604.
35. Carballo-Carbajal I, Weber-Endress S, Rovelli G et al.: Leucinerich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell Signal 2010, 22:821-827.
36. West AB, Moore DJ, Choi C et al.: Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 2007, 16:223-232. (Pubitemid 46179004)
37. Jaleel M, Nichols RJ, Deak M et al.: LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 2007, 405:307-317. (Pubitemid 47075166)
38. West AB, Moore DJ, Biskup S et al.: Parkinson's diseaseassociated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 2005, 102:16842-16847. (Pubitemid 41688864)
39. Nichols RJ, Dzamko N, Hutti JE et al.: Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J 2009, 424:47-60.
40. Gillardon F: Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability - a point of convergence in Parkinsonian neurodegeneration? J Neurochem 2009, 110:1514-1522.
41. Kanao T, Venderova K, Park DS et al.: Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila. Hum Mol Genet 2010, 19:3747-3758.
42. Imai Y, Gehrke S, Wang HQ et al.: Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 2008, 27:2432-2443.
43. Qing H, Wong W, McGeer EG, McGeer PL: Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun 2009, 387:149-152.
44. Lin C-H, Tsai P-I, Wu R-M, Chien C-T: LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of Tau by recruiting autoactivated GSK3{beta}. J Neurosci 2010, 30:13138-13149.
45. Kumar A, Greggio E, Beilina A et al.: The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4EBP compared to autophosphorylation. PLoS One 2010, 5:e8730.
46. Gloeckner CJ, Boldt K, von Zweydorf F et al.: Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the Nterminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. J Proteome Res 2010, 9:1738-1745.
47. Greggio E, Taymans JM, Zhen EY et al.: The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem Biophys Res Commun 2009, 389:449-454.
48. Webber PJ, Smith AD, Sen S et al.: Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J Mol Biol 2011, 412:94-110.
49. Kamikawaji S, Ito G, Iwatsubo T: Identification of the autophosphorylation sites of LRRK2. Biochemistry 2009, 48:10963-10975.
50. Li X, Tan YC, Poulose S et al.: Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 2007, 103:238-247. (Pubitemid 47404210)
51. Lewis PA, Greggio E, Beilina A et al.: The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 2007, 357:668-671. (Pubitemid 46653831)
52. Ito G, Okai T, Fujino G et al.: GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 2007, 46:1380-1388. (Pubitemid 46208485)
53. SmithWW, Pei Z, Jiang H et al.: Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006, 9:1231-1233. (Pubitemid 44454261)
54. Taymans JM, Vancraenenbroeck R, Ollikainen P et al.: LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS One 2011, 6:e23207.
55. Haebig K, Gloeckner CJ, Miralles MG et al.: ARHGEF7 (Beta- PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2. PLoS One 2010, 5:e13762.
56. Stafa K, Trancikova A, Webber P et al.: GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet 2012, 8:e1002527.
57. Moore DJ: The biology and pathobiology of LRRK2: Implications for Parkinson's disease. Parkinsonism Relat Disord 2008, 14:S92-S98.
58. Gloeckner CJ, Kinkl N, Schumacher A et al.: The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 2006, 15:223-232. (Pubitemid 43125977)
59. Greggio E, Cookson MR: Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009, 1.
60. Xiong Y, Coombes CE, Kilaru A et al.: GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet 2010, 6: e1000902.
61. Daniels V, Vancraenenbroeck R, Law BM et al.: Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem 2011, 116:304-315.
62. Smith WW, Pei Z, Jiang H et al.: Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A 2005, 102:18676-18681. (Pubitemid 43011285)
63. Ramsden N, Perrin J, Ren Z et al.: Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol 2011, 6:1021-1028.
64. Lee BD, Shin J-H, VanKampen J et al.: Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 2010, 16:998-1000.
65. Greggio E, Jain S, Kingsbury A et al.: Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006, 23:329-341. (Pubitemid 44097032)
66. Liu Z, Wang X, Yu Yet al.: A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A 2008, 105:2693-2698. (Pubitemid 351520575)
67. Liu Z, Hamamichi S, Lee BD et al.: Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum Mol Genet 2011, 20:3933-3942.
68. Ng CH, Mok SZ, Koh C et al.: Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci 2009, 29:11257-11262.
69. Dusonchet J, Kochubey O, Stafa K et al.: A Rat Model of Progressive Nigral Neurodegeneration Induced by the Parkinson's Disease-Associated G2019S Mutation in LRRK2. J Neurosci 2011, 31:907-912.
70. Deng X, Dzamko N, Prescott A et al.: Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol 2011, 7:203-205.
71. Ramonet D, Daher JPL, Lin BM et al.: Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2. PLoS One 2011, 6:e18568.
72. Li Y, Liu W, Oo TF et al.: Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009, 12:826-828.
73. Li X, Patel JC, Wang J et al.: Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci 2010, 1788-1797.
74. Melrose HL, Dächsel JC, Behrouz B et al.: Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenicmice.Neurobiol Dis 2010, 40:503-517.
75. Tong Y, Pisani A, Martella G et al.: R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A 2009, 106:14622-14627.
76. Shin N, Jeong H, Kwon J et al.: LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res 2008, 314:2055-2065.
77. Sakaguchi-Nakashima A, Meir JY, Jin Y et al.: LRK-1, a C. elegans PARK8-Related Kinase, Regulates Axonal-Dendritic Polarity of SV Proteins. Curr Biol 2007, 17:592-598. (Pubitemid 46497793)
78. Iaccarino C, Crosio C, Vitale C et al.: Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 2007, 16:1319-1326. (Pubitemid 47055127)
79. MacLeod D, Dowman J, Hammond R et al.: The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52:587-593. (Pubitemid 44781171)
80. Ho CC-Y, Rideout HJ, Ribe E et al.: The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via fasassociated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J Neurosci 2009, 29:1011-1016.
81. Conde C, Caceres A: Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci 2009, 10:319-332.
82. Plowey ED, Cherra SJ, Liu Y-J, Chu CT: Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 2008, 105:1048-1056. (Pubitemid 351565713)
83. Parisiadou L, Xie C, Cho HJ et al.: Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 2009, 29:13971-13980.
84. Chan D, Citro A, Cordy JM et al.: Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J Biol Chem 2011, 286:16140-16149.
85. Gandhi PN, Wang X, Zhu X et al.: The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res 2008, 86:1711-1720. (Pubitemid 351859422)
86. Lin X, Parisiadou L, Gu X-L et al.: Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease- Related Mutant [alpha]-synuclein. Neuron 2009, 64:807-827.
87. Kett LR, Boassa D, Ho CC-Y et al.: LRRK2 Parkinson disease mutations enhance its microtubule association. Hum Mol Genet 2012, 21:890-899.
88. Rajput A, Dickson DW, Robinson CA et al.: Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 2006, 67:1506-1508. (Pubitemid 44632090)
89. Higashi S, Moore DJ, Yamamoto R et al.: Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. J Neuropathol Exp Neurol 2009, 68:994-1005.
90. Lichtenberg M, Mansilla A, Zecchini VR et al.: The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death Dis 2011, 2:e196.
91. Gómez-Suaga P, Luzón-Toro B, Churamani D et al.: Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet 2011, 21:511-525.
92. Trancikova A, Tsika E, Moore DJ: Mitochondrial Dysfunction in Genetic Animal Models of Parkinson's Disease. Antioxid Redox Signal 2011, Oct 4, Epub.
93. Mortiboys H, Johansen KK, Aasly JO, Bandmann O: Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 2010, 75:2017-2020.
94. Wang X, Yan MH, Fujioka H et al.: LRRK2 Regulates Mitochondrial Dynamics and Function through Direct Interaction with DLP1. Hum Mol Genet 2012, Jan 6, Epub.